



## Ogier Guernsey advises Stanley Capital on new investment structure and acquisition of Noden Pharma

Deals - 01/10/2020

Ogier's Guernsey team has assisted Stanley Capital with the establishment of a Guernsey investment structure and the acquisition of Noden Pharma DAC and Noden Pharma USA (**Noden**), a leading speciality pharmaceutical company.

The multi-disciplinary Ogier team worked with Stanley Capital, lead counsel Willkie Farr & Gallagher (London) LLP and alterDomus. The team was led by partner Bryon Rees and senior associate Michelle Watson Bunn, with support from partners Tim Clipstone and Bryan De Verneuil-Smith, senior associate Charlotte Brown and associate Henry Simpson.

Bryon Rees commented: "We are delighted to have supported Stanley Capital and its advisors on this new investment structure and the initial acquisition, creating a solid base for future growth into a leading pharma platform."

Noden is focused on providing unique, complex to manufacture prescription medicines for cardiovascular patients who are intolerant to mainstream treatments. It is the first acquisition and a core platform for implementing a strategy to consolidate the mature product speciality pharma marketplace. Stanley Capital, working alongside Noden's management team, will pursue a value investment philosophy, targeting the acquisition of multiple drug portfolios to create a differentiated and highly cash generative portfolio of attractive medicines with established operational, technical, or patent-led barriers to entry.

Simon Cottle, partner at Stanley Capital, said: "The acquisition of Noden is the culmination of years of thematic research into the specialty pharmaceuticals sector, which identified the company as a strong buy and build platform. We look forward to working with Noden's excellent management team and our industry advisors to build the company into a leading pharma platform, providing essential treatments for patients with unique and difficult to treat conditions."

Stanley Capital is a private equity partnership pursuing repeatable relative value and thematic investment strategies in technology, healthcare, and sustainability, targeting businesses with enterprise values of \$250mn to \$2.5bn.

## About Ogier

Ogier is a professional services firm with the knowledge and expertise to handle the most demanding and complex transactions and provide expert, efficient and cost-effective services to all our clients. We regularly win awards for the quality of our client service, our work and our people.

## Disclaimer

This client briefing has been prepared for clients and professional associates of Ogier. The information and expressions of opinion which it contains are not intended to be a comprehensive study or to provide legal advice and should not be treated as a substitute for specific advice concerning individual situations.

Regulatory information can be found under [Legal Notice](#)

## Meet the Author



Bryon Rees

Partner

Guernsey

E: [bryon.rees@ogier.com](mailto:bryon.rees@ogier.com)

T: [+44 1481 752312](tel:+441481752312)

## Key Contacts



Tim Clipstone

Partner

British Virgin Islands

Guernsey

E: [tim.clipstone@ogier.com](mailto:tim.clipstone@ogier.com)

T: [+44 1481 752265](tel:+441481752265)



Bryan De Verneuil-Smith

Partner

Guernsey

E: [bryan.deverneuil-smith@ogier.com](mailto:bryan.deverneuil-smith@ogier.com)

T: [+44 1481 752357](tel:+441481752357)



Michelle Watson Bunn

Managing Associate

Guernsey

E: [michelle.watsonbunn@ogier.com](mailto:michelle.watsonbunn@ogier.com)

T: [+44 1481 752220](tel:+441481752220)

## Related Services

[Banking and Finance](#)

[Corporate](#)

[Investment Funds](#)

[Mergers and Acquisitions](#)

[Legal](#)

[Consulting](#)

## Related Sectors

[Funds Hub](#)